Allsino Pharmaceutical Co., Ltd. (a wholly-owned subsidiary of Nuotai Biotech, Stock Code: 688076) was founded in May 2004, with a small molecule & peptide R&D center located in Hangzhou, Zhejiang, and a GMP commercial production base situated in Jiande, Zhejiang. As an international enterprise, Allsino specializes in the research, development, and production of small molecule new drugs, advanced intermediates, and peptide fragments. It remains committed to driving innovation through technological advancements and has established a quality management system compliant with USFDA, EDQM, and NMPA standards. The company provides compliant and efficient CDMO services to globally renowned pharmaceutical enterprises.
